Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

Hernan Carol, Ingrid Boehm, C. Patrick Reynolds, Min H. Kang, John M. Maris, Christopher L. Morton, Richard Gorlick, E. Anders Kolb, Stephen T. Keir, Jianrong Wu, Amy E. Wozniak, Yu Yang, Mark Manfredi, Jeffrey Ecsedy, Jianmin Wang, Geoffrey Neale, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: To gain a greater understanding of the potential of the Aurora kinase A inhibitor MLN8237 in the treatment of pediatric malignancies. Methods: The activity of MLN8237 was evaluated against 28 neuroblastoma and Ewing sarcoma cell lines, and its in vivo efficacy was studied over a range of doses against 12 pediatric tumor xenograft models. Pharmacokinetic, pharmacodynamic, and genomic studies were undertaken. Results: In vitro neuroblastoma cell lines were generally more sensitive to MLN8237 than Ewing sarcoma lines. MLN8237 demonstrated significant activity in vivo against solid tumor models at the maximum tolerated dose (MTD); however, only 2 of 6 neuroblastoma models had objective responses at 0.25MTD. In contrast, MLN8237 induced objective responses at its MTD and at 0.5MTD in three ALL models and in two out of three at 0.25MTD. Pharmacokinetic studies at 0.5MTD demonstrated a T max of 0.5 h, C max of 24.8 μM, AUC (0-24) of 60.3 μM h, and 12 h trough level of 1.2 μM. Mitotic indices increased 6-12 h after MLN8237 administration. AURKA copy number variation was frequent in xenografts, and expression was highly correlated with copy number. Conclusions: Objective responses were more frequent in tumors with decreased AURKA copy number (5/8) compared to those with increased gene copy number (2/14). This report confirms the significant activity against both solid tumor and ALL xenografts at the MTD, with a steep dose response. These data support clinical development of MLN8237 in childhood cancer. Because of the steep dose-response relationship, such studies should target achieving trough levels of 1 μM or higher for sustained periods of treatment.

Original languageEnglish (US)
Pages (from-to)1291-1304
Number of pages14
JournalCancer Chemotherapy and Pharmacology
Volume68
Issue number5
DOIs
StatePublished - Nov 2011

Fingerprint

Aurora Kinase A
Pharmacodynamics
Pediatrics
Pharmacokinetics
Maximum Tolerated Dose
Tumors
Neuroblastoma
Neoplasms
Heterografts
Ewing's Sarcoma
Cells
Cell Line
Mitotic Index
Gene Dosage
MLN 8237
Area Under Curve
Genes

Keywords

  • Developmental therapeutics
  • MLN8237
  • Pediatric cancer
  • Preclinical testing

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. / Carol, Hernan; Boehm, Ingrid; Reynolds, C. Patrick; Kang, Min H.; Maris, John M.; Morton, Christopher L.; Gorlick, Richard; Kolb, E. Anders; Keir, Stephen T.; Wu, Jianrong; Wozniak, Amy E.; Yang, Yu; Manfredi, Mark; Ecsedy, Jeffrey; Wang, Jianmin; Neale, Geoffrey; Houghton, Peter J.; Smith, Malcolm A.; Lock, Richard B.

In: Cancer Chemotherapy and Pharmacology, Vol. 68, No. 5, 11.2011, p. 1291-1304.

Research output: Contribution to journalArticle

Carol, H, Boehm, I, Reynolds, CP, Kang, MH, Maris, JM, Morton, CL, Gorlick, R, Kolb, EA, Keir, ST, Wu, J, Wozniak, AE, Yang, Y, Manfredi, M, Ecsedy, J, Wang, J, Neale, G, Houghton, PJ, Smith, MA & Lock, RB 2011, 'Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer', Cancer Chemotherapy and Pharmacology, vol. 68, no. 5, pp. 1291-1304. https://doi.org/10.1007/s00280-011-1618-8
Carol, Hernan ; Boehm, Ingrid ; Reynolds, C. Patrick ; Kang, Min H. ; Maris, John M. ; Morton, Christopher L. ; Gorlick, Richard ; Kolb, E. Anders ; Keir, Stephen T. ; Wu, Jianrong ; Wozniak, Amy E. ; Yang, Yu ; Manfredi, Mark ; Ecsedy, Jeffrey ; Wang, Jianmin ; Neale, Geoffrey ; Houghton, Peter J. ; Smith, Malcolm A. ; Lock, Richard B. / Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 68, No. 5. pp. 1291-1304.
@article{6d395b75358c488cbba81b884f74bcd9,
title = "Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer",
abstract = "Purpose: To gain a greater understanding of the potential of the Aurora kinase A inhibitor MLN8237 in the treatment of pediatric malignancies. Methods: The activity of MLN8237 was evaluated against 28 neuroblastoma and Ewing sarcoma cell lines, and its in vivo efficacy was studied over a range of doses against 12 pediatric tumor xenograft models. Pharmacokinetic, pharmacodynamic, and genomic studies were undertaken. Results: In vitro neuroblastoma cell lines were generally more sensitive to MLN8237 than Ewing sarcoma lines. MLN8237 demonstrated significant activity in vivo against solid tumor models at the maximum tolerated dose (MTD); however, only 2 of 6 neuroblastoma models had objective responses at 0.25MTD. In contrast, MLN8237 induced objective responses at its MTD and at 0.5MTD in three ALL models and in two out of three at 0.25MTD. Pharmacokinetic studies at 0.5MTD demonstrated a T max of 0.5 h, C max of 24.8 μM, AUC (0-24) of 60.3 μM h, and 12 h trough level of 1.2 μM. Mitotic indices increased 6-12 h after MLN8237 administration. AURKA copy number variation was frequent in xenografts, and expression was highly correlated with copy number. Conclusions: Objective responses were more frequent in tumors with decreased AURKA copy number (5/8) compared to those with increased gene copy number (2/14). This report confirms the significant activity against both solid tumor and ALL xenografts at the MTD, with a steep dose response. These data support clinical development of MLN8237 in childhood cancer. Because of the steep dose-response relationship, such studies should target achieving trough levels of 1 μM or higher for sustained periods of treatment.",
keywords = "Developmental therapeutics, MLN8237, Pediatric cancer, Preclinical testing",
author = "Hernan Carol and Ingrid Boehm and Reynolds, {C. Patrick} and Kang, {Min H.} and Maris, {John M.} and Morton, {Christopher L.} and Richard Gorlick and Kolb, {E. Anders} and Keir, {Stephen T.} and Jianrong Wu and Wozniak, {Amy E.} and Yu Yang and Mark Manfredi and Jeffrey Ecsedy and Jianmin Wang and Geoffrey Neale and Houghton, {Peter J.} and Smith, {Malcolm A.} and Lock, {Richard B.}",
year = "2011",
month = "11",
doi = "10.1007/s00280-011-1618-8",
language = "English (US)",
volume = "68",
pages = "1291--1304",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

AU - Carol, Hernan

AU - Boehm, Ingrid

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Maris, John M.

AU - Morton, Christopher L.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Keir, Stephen T.

AU - Wu, Jianrong

AU - Wozniak, Amy E.

AU - Yang, Yu

AU - Manfredi, Mark

AU - Ecsedy, Jeffrey

AU - Wang, Jianmin

AU - Neale, Geoffrey

AU - Houghton, Peter J.

AU - Smith, Malcolm A.

AU - Lock, Richard B.

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To gain a greater understanding of the potential of the Aurora kinase A inhibitor MLN8237 in the treatment of pediatric malignancies. Methods: The activity of MLN8237 was evaluated against 28 neuroblastoma and Ewing sarcoma cell lines, and its in vivo efficacy was studied over a range of doses against 12 pediatric tumor xenograft models. Pharmacokinetic, pharmacodynamic, and genomic studies were undertaken. Results: In vitro neuroblastoma cell lines were generally more sensitive to MLN8237 than Ewing sarcoma lines. MLN8237 demonstrated significant activity in vivo against solid tumor models at the maximum tolerated dose (MTD); however, only 2 of 6 neuroblastoma models had objective responses at 0.25MTD. In contrast, MLN8237 induced objective responses at its MTD and at 0.5MTD in three ALL models and in two out of three at 0.25MTD. Pharmacokinetic studies at 0.5MTD demonstrated a T max of 0.5 h, C max of 24.8 μM, AUC (0-24) of 60.3 μM h, and 12 h trough level of 1.2 μM. Mitotic indices increased 6-12 h after MLN8237 administration. AURKA copy number variation was frequent in xenografts, and expression was highly correlated with copy number. Conclusions: Objective responses were more frequent in tumors with decreased AURKA copy number (5/8) compared to those with increased gene copy number (2/14). This report confirms the significant activity against both solid tumor and ALL xenografts at the MTD, with a steep dose response. These data support clinical development of MLN8237 in childhood cancer. Because of the steep dose-response relationship, such studies should target achieving trough levels of 1 μM or higher for sustained periods of treatment.

AB - Purpose: To gain a greater understanding of the potential of the Aurora kinase A inhibitor MLN8237 in the treatment of pediatric malignancies. Methods: The activity of MLN8237 was evaluated against 28 neuroblastoma and Ewing sarcoma cell lines, and its in vivo efficacy was studied over a range of doses against 12 pediatric tumor xenograft models. Pharmacokinetic, pharmacodynamic, and genomic studies were undertaken. Results: In vitro neuroblastoma cell lines were generally more sensitive to MLN8237 than Ewing sarcoma lines. MLN8237 demonstrated significant activity in vivo against solid tumor models at the maximum tolerated dose (MTD); however, only 2 of 6 neuroblastoma models had objective responses at 0.25MTD. In contrast, MLN8237 induced objective responses at its MTD and at 0.5MTD in three ALL models and in two out of three at 0.25MTD. Pharmacokinetic studies at 0.5MTD demonstrated a T max of 0.5 h, C max of 24.8 μM, AUC (0-24) of 60.3 μM h, and 12 h trough level of 1.2 μM. Mitotic indices increased 6-12 h after MLN8237 administration. AURKA copy number variation was frequent in xenografts, and expression was highly correlated with copy number. Conclusions: Objective responses were more frequent in tumors with decreased AURKA copy number (5/8) compared to those with increased gene copy number (2/14). This report confirms the significant activity against both solid tumor and ALL xenografts at the MTD, with a steep dose response. These data support clinical development of MLN8237 in childhood cancer. Because of the steep dose-response relationship, such studies should target achieving trough levels of 1 μM or higher for sustained periods of treatment.

KW - Developmental therapeutics

KW - MLN8237

KW - Pediatric cancer

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=82455192242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455192242&partnerID=8YFLogxK

U2 - 10.1007/s00280-011-1618-8

DO - 10.1007/s00280-011-1618-8

M3 - Article

VL - 68

SP - 1291

EP - 1304

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -